Advanced search
Start date

BioMOF (Biocompatible Metal-Organic Framework) of zinc as a system for the release of metal-drugs with anticancer activity

Grant number: 17/13961-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): September 01, 2017
Effective date (End): December 08, 2020
Field of knowledge:Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry
Principal Investigator:Regina Celia Galvao Frem
Grantee:Renan Augusto Marson Armando
Home Institution: Instituto de Química (IQ). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Associated scholarship(s):19/26746-5 - MOF@MOF core-shell superstructures as bimodal drug-delivery systems, BE.EP.IC


Drug delivery systems are among the segments with the greatest potential for application in the pharmaceutical industry, due to the possibility of optimizing the therapeutic effects and reducing the adverse effects inherent to the drug. Currently, the most widely used systems for drug delivery are liposomes, nanoparticles, nanoemulsions or micelles, the main limitation of which is associated with the low drug incorporation capacity, generally less than 5% by weight of the drug transported relative to the carrier materials. In order to overcome this pharmacological barrier, new systems have been studied and developed, among them a new porous material known as MOF (Metal-Organic Framework). Metal-organic framework belong to a new class of materials of the group of coordination polymers and are highly designed crystalline solids with covalent capacity between metal ions or clusters and polydentate organic binders. There are no doubts and topical about biological applications of this class of materials, such as BioMOFs, biocompatible MOFs, which are constructed from biologically compatible building blocks such as bioelements (Zn, Fe, Cu) and binders such as amino acids, peptides, Nitrogenic bases, etc. In recent years, the interest in obtaining new metal-based drugs for the treatment of cancer has considerably increased. A discovery of the biological activity of cisplatin and its subsequent as an untreated cancer drug has boosted the study of numerous analogous complexes, which generally exhibited similarities in antitumor activity. (II), coordination compounds containing Pd (II) are being investigated for the same purpose. Thus, this work aims to synthesize a BioMoF-1, obtained from the interaction between Zn (II) ions, adenine and the 4,4'-biphenyldicarboxylic linker, and to investigate the potential use of this material as PdCl (PPh3) L)] (PPh3 = triphenylphosphine, L = N-ethyl-1-iminothiolate-3,5-dimethylpyrazole or frambionathiosemicarbazone), which have proven anticancer properties (IC 50 <1 ¼mol L -1 for a breast cancer lineage MCF-7). (AU)